Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Coca-Cola

These are stocks investors can buy today and forget about.

2 Stocks You Can Keep Forever: ABT & KO

Hint: Its market cap is over $150 billion, and the company was founded when Grover Cleveland was president.

Here's a Blue-Chip Stock You'd Probably Never Guess Would Profit From Marijuana Legalization

Abbott Laboratories ABT, +0.12% said Friday its board has approved a 12.5% increase in its quarterly dividend to 36 cents a share.

Abbott Labs raises quarterly dividend by 12.5% to 36 cents a share

Here's how the healthcare giant scores on growth prospects, dividend, and valuation.

Is Abbott Laboratories (ABT) Stock a Buy?

ABT stock is one of the biggest diversified medical stocks behind Johnson & Johnson and Roche. As it aims for clearance of its Freestyle Libre 2, is it time to buy Abbott stock?

Abbott Is One Of The Biggest Medical Stocks — Should You Buy ABT Stock Now?

Bristol-Myers

Dollar General

These stocks are great picks to own regardless of which turns the market takes.

3 Stocks to Buy Ahead of the Next Market Crash: ABT, BMY & DG

Johnson & Johnson

Which stock wins in a matchup between these two healthcare giants?

Better Buy: Abbott Laboratories vs. Johnson & Johnson

DexCom

Medtronic

With digital diabetes management space rapidly gaining momentum, patients with diabetes can look forward to better and improved outcomes.

Digital Diabetes Management Gains Momentum: 3 Stocks in Focus

Donaldson

Entergy LA 4.875 % Bonds 2016-01.09.66 Collateral Trust Mtg

Old National Bancorp

Schlumberger

The investment firm Mairs and Power (Trades, Portfolio) sold shares of the following stocks during the third quarter.

Mairs and Power Sells UPS, Abbott Labs and more

Air Products and Chemicals

Chubb

Retired investors will especially like these reliable and solid dividend stocks.

3  Dividend Aristocrats to Buy and Hold Forever.

Abbott (ABT) reported earnings 30 days ago. What's next for the stock?

Abbott (ABT) Up 2.1% Since Last Earnings Report: Can It Continue?

After nearly 21 years at Abbott Laboratories (NYSE: ABT), CEO Miles White is preparing for his departure.

Abbott CEO Miles White Steps Down

Abbott Laboratories announced Wednesday that Chief Operating Officer Robert Ford would succeed Chief Executive Officer Miles White in March. Abbott stock dipped a fraction in early trading.

Medtech Giant Elects New CEO As 21-Year Veteran Steps Down

Abbott Laboratories ABT, +0.69% said Wednesday that Chief Executive Miles White will step down on March 31, 2020, after 21 years in the role.

Abbott Laboratories CEO Miles White to step down after 2 decades in charge

Abbott Laboratories chief executive Miles White is stepping down effective next year after 21 years at the helm of the diversified healthcare company.

Abbott Labs CEO Miles White Stepping Down After Two Decades

AmerisourceBergen

Cardinal Health

Penumbra

Varian Medical Systems

DENTSPLY SIRONA

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Medical Products' Nov 7 Earnings Roster: ABC, CAH & More

Abbott Laboratories: Predictability In Q4

ABIOMED

IDEXX Laboratories

Integer Holdings

Teleflex

Earnings and revenues for the Medical Instruments sector in the third quarter are likely to have declined sequentially. Read to know how a few companies from the sector might have fared in the period.

Medical Instruments' Oct 31 Earnings Roster: IDXX, ABMD & More

Abbott is a diversified healthcare conglomerate with a global presence. The firm operates in four main segments: Medical Devices, Diagnostics, Nutritional, and Established Pharmaceuticals.

How Much Can Abbott’s Revenue Grow In The Coming Years?

Novo Nordisk

Which stock wins in a battle between these two healthcare giants?

Better Buy: Abbott Laboratories vs.  Novo Nordisk

Baxter

Labcorp Holdings Inc

ResMed

Medical Products' Oct 24 Earnings Roster: BAX, CERN & More

Adobe

Netflix

ServiceNow

Workday

Adobe, Netflix, ServiceNow, Workday and Abbott Labs were our top stock trades from Wednesday. Here's a look at the charts.

5 Top Stock Trades for Thursday: ADBE, NFLX, ABT, NOW & WDAY

Abbott Laboratories (ABT) CEO Miles White on Q3 2019 Results - Earnings Call Transcript

Here's a quick rundown on how the healthcare giant performed.

3 Things You'll Want to Know About Abbott Labs' Q3 Results

We are optimistic about Abbott's (ABT) strong and consistent EPD and Medical Devices performance organically.

News for Abbott Labs Stock (ABT)